Mutations in epigenetic modifiers (14 of 21, 67%), NPM1 (5 of 5, 100%), and SRSF2 (2 of 2, 100%) appear to be more stable in IEM‐AML relapse, while mutations in signal transduction pathways (7 of 15, 47%), myeloid transcription factors (1 of 3, 33%), and tumor suppressor genes (0 of 2, 0%) were relatively unstable and were most frequently lost or acquired at relapse. The gene discussed is SRSF2; the disease is acute myeloid leukemia.